Regorafenib, ipilimumab, and nivolumab (RIN) in chemotherapy-resistant MSS metastatic colorectal cancer (mCRC).

被引：0
|
作者：
Fakih, Marwan
Sandhu, Jaideep Singh
Lim, Dean
Li, Sierra
Wang, Chongkai
机构：
[1] City Hope Natl Comprehens Canc Ctr, Duarte, CA USA
[2] City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
110
引用
收藏
页码：110 / 110
页数：1
相关论文
共 50 条
  • [41] Assessing QoL in patients with metastatic colorectal cancer (mCRC) treated with chemotherapy
    Miller, KL
    Johnson, LL
    Colwell, HH
    Bhattacharyya, SK
    Deeter, RG
    Mathias, SD
    VALUE IN HEALTH, 2005, 8 (06) : A49 - A49
  • [42] Pharmacokinetics of regorafenib in the phase 3 CONCUR and CORRECT trials in patients with metastatic colorectal cancer (mCRC)
    Cleton, A.
    Sturm, I.
    Trnkova, Z. Jirakova
    Grevel, J.
    Fiala-Buskies, S.
    Lettieri, J.
    ANNALS OF ONCOLOGY, 2015, 26
  • [43] Longitudinal patterns of chemotherapy (CT) use in metastatic colorectal cancer (mCRC)
    Herndon, J. E., II
    Zafar, Y.
    Marcello, J.
    Wheeler, J.
    Rowe, K.
    Morse, M. A.
    Abernethy, A. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [44] First line capecitabine (Xeloda®) chemotherapy for metastatic colorectal cancer (MCRC)
    Kovcin, V
    Krivokapic, Z
    Jesic, R
    INTERNATIONAL JOURNAL OF CANCER, 2002, : 228 - 228
  • [45] EFFICACY OF LARGE-VOLUME PLASMA-EXCHANGE IN PATIENTS WITH CHEMOTHERAPY-RESISTANT METASTATIC COLORECTAL-CANCER
    BEYER, JH
    SCHUFFWERNER, P
    KOSTERING, H
    KABOTH, U
    RICHNER, J
    NAGEL, GA
    ONCOLOGY, 1985, 42 (02) : 72 - 79
  • [46] Modulation of autophagy: a Phase II study of vorinostat plus hydroxychloroquine versus regorafenib in chemotherapy-refractory metastatic colorectal cancer (mCRC)
    Arora, Sukeshi Patel
    Tenner, Laura
    Sarantopoulos, John
    Morris, Jay
    Liu, Qianqian
    Mendez, Jenny A.
    Curiel, Tyler
    Michalek, Joel
    Mahalingam, Devalingam
    BRITISH JOURNAL OF CANCER, 2022, 127 (06) : 1153 - 1161
  • [47] Modulation of autophagy: a Phase II study of vorinostat plus hydroxychloroquine versus regorafenib in chemotherapy-refractory metastatic colorectal cancer (mCRC)
    Sukeshi Patel Arora
    Laura Tenner
    John Sarantopoulos
    Jay Morris
    Qianqian Liu
    Jenny A. Mendez
    Tyler Curiel
    Joel Michalek
    Devalingam Mahalingam
    British Journal of Cancer, 2022, 127 : 1153 - 1161
  • [48] Regorafenib for metastatic colorectal cancer Reply
    Van Cutsem, Eric
    Grothey, Axel
    LANCET, 2013, 381 (9877): : 1538 - 1539
  • [49] Regorafenib: A Review in Metastatic Colorectal Cancer
    Dhillon, Sohita
    DRUGS, 2018, 78 (11) : 1133 - 1144
  • [50] Management of chemotherapy-resistant breast cancer
    Miles, DW
    Rubens, RD
    BREAST, 1996, 5 (04): : 288 - 292
12345